Abdrakhmanov_2024_Caspian.J.Intern.Med_15_499

BACKGROUND: Allelic variants of genes encoding enzymes of the esterase system (CES1) and P-glycoprotein (ABCB1) can change the metabolism and pharmacokinetics of dabigatran. Therefore, they act as determining factors in the development of side effects, especially bleeding. We analyzed the genotype-phenotype relationship of ABCB1 (rs1045642, rs4148738, rs2032582, and rs1128503) and CES1 (rs8192935, rs71647871, and rs2244613) polymorphisms in patients with atrial fibrillation who had been treated with dabigatran. METHODS: A total of 150 patients were recruited for this study. TaqMan technology was used for SNP genotyping. RESULTS: Patients with the rs2244613 GG genotype had a lower concentration (55.27 +/- 34.22 ng/ml) compared to those with the TT genotype (63.33 +/- 52.25 ng/ml) (additive model, P = 0.000). Individuals with the rs8192935 AA genotype had a lower concentration (52.72 +/- 30.45 ng/ml) compared to those with the GG genotype (79.78 +/- 57 ng/ml) (additive model, P = 0.001). The APTT values among the different genotypes of the ABCB1 SNPs, rs4148738 and rs1045642, were significantly different (P = 0.035 and P = 0.024, respectively). CONCLUSION: Our research demonstrates that the CES1 polymorphisms, rs8192935 and rs2244613, are associated with the pharmacodynamics and pharmacokinetics of dabigatran in the Kazakh subpopulation.